TP53 and cancer: PRIMA-1 and its methylated form PRIMA-1Met (APR-246), a non-genotoxic candidate drug for mutant p53 reactivation, have been shown to induce p53-mediated apoptosis and cell cycle arrest in different types of cancer as well as be potent inducers of oxidative stress [39].